Ecolab Inc. (ECL) Stock Price & Analysis
Ecolab Inc. (ECL) rose 2.13% to USD 268.75 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
ECL last closed at USD 263.14; the session ranged USD 263.4–268.83 on volume of 837,644 shares. Market capitalization is $75.64B, with a 52-week range of USD 243.15–309.27 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 268.75 |
|---|---|
| Change | ▲ 2.13% (up) |
| Previous Close | USD 263.14 |
| Open | USD 263.75 |
| Day Range | USD 263.4 – 268.83 |
| 52-Week Range | USD 243.15 – 309.27 |
| Volume | 837,644 shares |
| Market Cap | $75.64B |
| Exchange | NYQ |
Technical Analysis (ECL)
Nexqual's technical model rates ECL "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.02 (neutral) |
| vs SMA50 | Above (USD 265.36) |
| MACD | -0.63 (negative) |
Analyst Ratings (ECL)
Wall Street analysts rate ECL "Buy" based on 21 analysts, with a mean price target of USD 319.43 (range USD 275–345), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 319.43 |
| High Target | USD 345 |
| Low Target | USD 275 |
| Buy / Hold / Sell | 20 / 6 / 0 |
Earnings (ECL)
| Next Earnings Date | 2026-07-28 |
|---|---|
| EPS Estimate | USD 2.08 |
| Revenue Estimate | $4.39B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.7 vs est 1.7 ▲ beat |
| 2025-12-31 | USD 2.08 vs est 2.07 ▲ beat |
| 2025-09-30 | USD 2.07 vs est 2.07 ▼ miss |
| 2025-06-30 | USD 1.89 vs est 1.9 ▼ miss |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (ECL)
| Total Revenue | $16.45B |
|---|---|
| Revenue Growth (YoY) | +10.00% |
| Gross Margin | +44.37% |
| Operating Margin | +16.93% |
| Profit Margin | +12.80% |
| ROE | +22.43% |
| Debt / Equity | 92.37 |
| Current Ratio | 0.99 |
| Total Cash | $519.80M |
| Total Debt | $9.27B |
| Free Cash Flow | $1.59B |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (ECL)
Nexqual rates Ecolab Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Mixed — Revenue +2.2% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 17% |
| Balance Sheet | Weak — $520M cash vs $9.27B debt |
| Cash Flow | Solid — FCF $1.59B, 10% margin |
| Efficiency | Strong — ROE 22%, ROA 8.0% |
Ownership (ECL)
| Insider Ownership | +0.16% |
|---|---|
| Institutional Ownership | +93.55% |
| Shares Outstanding | 281.44M |
| Float | 280.85M |
| Short % of Float | +1.47% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (ECL)
Ecolab Inc. is led by Christophe Beck (age 57), CEO, President & Chairman of the Board, per Nexqual as of July 25, 2026 at 01:12 UTC.
| CEO, President & Chairman of the Board | Christophe Beck (age 57) |
|---|---|
| Chief Financial Officer | Scott D. Kirkland (age 51) |
| Executive Vice President of Human Resources | Margeaux M. King (age 47) |
| Co-Chief Operating Officer of Global Markets | Darrell R. Brown (age 61) |
| Co-Chief Operating Officer of Global Businesses | Gregory Russell B. Cook (age 56) |
Major Backers & Investors (ECL)
Notable institutional backers of Ecolab Inc. include JPMorgan, Morgan Stanley, Gates Foundation Trust, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 4.14% |
| Morgan Stanley | 2.77% |
| Gates Foundation Trust | 1.85% |
| Aristotle Capital Management, LLC | 1.32% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.27% |
| Fidelity | 1.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.81% |
| BlackRock | 9.29% |
| State Street | 5.08% |
| Geode Capital | 2.13% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Ecolab Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Today, we have $16 billion in annual sales, 48,000 associates and customers in more than 170 countries and 40 industries.
- As we expand the use of smart, connected devices, we believe our Pest Intelligence model will further contribute to our high-quality outcomes. ​ Global Life Sciences ​ This reportable segment consists of the Life Sciences operating segment. ​ Life Sciences ​ Life Sciences provides end-to-end cleaning and contamination control solutions to pharmaceutical and personal care manufacturers.
- We believe we are one of the leading suppliers of process purification solutions in Europe and North America and of contamination control solutions in Europe, with a growing presence in North America and other regions. ​ ​ 6 Table of Contents Additional Information ​ International Operations ​ We directly operate in approximately 100 countries outside of the United States through wholly-owned subsidiaries or, in some cases, through a joint venture with a local partner.
- This unique combination enables us to partner with customers to define what best-in-class looks like and scale it across their operations, helping them achieve peak performance.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| APD | Air Products and Chemicals, Inc | USD 297.87 | ▲ 0.29% |
| SHW | Sherwin-Williams Company (The) | USD 317.51 | ▼ 0.75% |
| CTAS | Cintas Corporation | USD 205.91 | ▲ 2.26% |
| DOV | Dover Corporation | USD 202.2 | ▼ 5.75% |
| PPG | PPG Industries, Inc. | USD 116 | ▼ 1.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.